Revenue rose 11.63% to ¥27.62 billion and net profit grew 18.05% to ¥3.37 billion, driven by strong CHC and prescription drug growth. Major integration and M&A moves, robust cash flow, and a 50% dividend payout highlight the year.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.